XM does not provide services to residents of the United States of America.
N
N

Novartis


News

Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN

BRIEF-Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN Oct 24 (Reuters) - NOVARTIS AG NOVN.S : RIBOCICLIB (KISQALI®) RECOGNIZED AS CATEGORY 1 PREFERRED BREAST CANCER ADJUVANT TREATMENT BY NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) Source text for Eikon: ID:nGNERj7p9
N

US FDA declines to approve Camurus' rare hormone disorder drug

US FDA declines to approve Camurus' rare hormone disorder drug Oct 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday. WHY IT'S IMPORTANT The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of ev
I
N

Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Oct 18 (Reuters) - Novartis AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI® TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nPn6w07lka Fur
N

Novartis Receives Positive CHMP Opinion For Kisqali

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali Oct 18 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER CHMP RECOMMENDS MARKETING AUTHORIZATION FOR NOVARTIS' KISQALI KISQALI REDUCES RECURRENCE RISK BY 25% IN PHASE III NATALEE
N

S&P 500 ends flat; health insurer declines offset chip gains

LIVE MARKETS-S&P 500 ends flat; health insurer declines offset chip gains Dow ends up ~0.4%, while S&P 500, Nasdaq close roughly flat Utilities lead S&P 500 sector decliners; Energy up most Dollar, crude, gold gain; bitcoin declines U.S. 10-Year Treasury yield jumps to ~4.10% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U
B

Consumer groups ask FTC to block Novo Holdings-Catalent deal

UPDATE 7-Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing Adds Novo Holdings comment in paragraph 7 By Jody Godoy and Maggie Fick NEW YORK, Oct 18 (Reuters) - U.S.
A
A
N
N
P
R

Factors to consider as earnings season heats up

LIVE MARKETS- Factors to consider as earnings season heats up Main U.S. indexes modestly green; Nasdaq out front, up ~0.5% Tech leads S&P sector gainers; Real Estate weakest group Dollar, gold gain; crude ~flat; bitcoin declines U.S. 10-Year Treasury yield jumps to ~4.10% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U
B

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing By Jody Godoy, Maggie Fick NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S.
A
A
N
N
P
R

Record highs have felt good, but maybe too good?

LIVE MARKETS-Record highs have felt good, but maybe too good? Main U.S. indexes modestly green; Nasdaq out front, up ~0.6% Tech leads S&P sector gainers; Real Estate weakest group Dollar, gold gain; crude edges red; bitcoin dips U.S. 10-Year Treasury yield jumps to ~4.09% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U
B

Thursday economics roundup: Solid footing, soft landings

LIVE MARKETS-Thursday economics roundup: Solid footing, soft landings Main U.S. stock indexes modestly green Tech leads S&P sector gainers; Real Estate down the most Euro STOXX 600 index up ~0.8%; ECB cuts rates 25 bps Dollar, gold, crude gain; bitcoin dips U.S. 10-Year Treasury yield jumps to ~4.09% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
B
N
N
U
U

US equities edge up early as chipmakers rise

LIVE MARKETS-US equities edge up early as chipmakers rise Main U.S. stock indexes modestly green Tech leads S&P sector gainers; Real Estate down the most Euro STOXX 600 index up ~0.8%; ECB cuts rates 25 bps Dollar, gold, crude gain; bitcoin off ~1% U.S. 10-Year Treasury yield jumps to ~4.09% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U

Biotech investors stay on sidelines as US election looms

LIVE MARKETS-Biotech investors stay on sidelines as US election looms Main U.S. stock indexes up early Technology leads S&P 500 sector gains; real estate down the most Euro STOXX 600 index up ~0.9%; ECB cuts rates 25 bps Dollar, gold, crude gain; bitcoin dips U.S. 10-Year Treasury yield rises to ~4.09% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U

Broader market spreads its wings

LIVE MARKETS-Broader market spreads its wings Main U.S. equity index futures green: Nasdaq 100 up ~0.9% Initial jobless claims 241k vs 260k est Sep Retail Sales MM > est; Ex-Autos > est Euro STOXX 600 index up ~0.8%; ECB cuts rates 25 bps Dollar, gold, crude gain; bitcoin declines U.S. 10-Year Treasury yield rises to ~4.07% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
N
N
U
U

Big oil cash return resilience in spotlight for 2025 - BofA

LIVE MARKETS-Big oil cash return resilience in spotlight for 2025 - BofA STOXX 600 up 0.6% TSMC beat, earnings provide support ECB in focus Banks lead gainers Nasdaq futures rise Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com BIG OIL CASH RETURN RESILIENCE IN SPOTLIGHT FOR 2025 - BOFA When it comes to Big Oil, Bank of America is on a quest for cash return resilience - understand
E
N
N
O
R
G
E
F
S
U
G

Roche and Novartis topple Nestle in tight race

LIVE MARKETS-Roche and Novartis topple Nestle in tight race STOXX 600 up 0.6% TSMC beat, earnings provide support ECB in focus Banks lead gainers Nasdaq futures rise Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com ROCHE AND NOVARTIS TOPPLE NESTLE IN TIGHT RACE There is a tight race quietly unfolding in Zurich.
N
N
R
A
E
F
S
U
G

Swiss trade surplus at CHF 4.946 bln in September

TABLE-Swiss trade surplus at CHF 4.946 bln in September Oct 17 (Reuters) - Switzerland ran a merchandise trade surplus of 4.946 billion Swiss francs in September, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) September 2024 August 2024 Imports 17.579 15.905 Exports 22.526 20.649 Balance 4.946 4.744 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Swiss stocks - Factors to watch on October 17

Swiss stocks - Factors to watch on October 17 ZURICH/GDANSK, Oct 17 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: NESTLE NESN.S Nestle cut its full-year sales outlook and reported worse-than-expected nine-month organic sales growth on Thursday as the world's biggest packaged food company failed to grow volumes amid continued price hikes.
A
N
N
S
S

Novartis loses latest bid to block generic version of blockbuster heart drug

Novartis loses latest bid to block generic version of blockbuster heart drug By Brendan Pierson Oct 16 (Reuters) - Novartis NOVN.S has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it, though the generic's launch faces other legal roadblocks. U.S. District Judge Dabney Friedrich in Washington, D.C., in an order made public on Tuesday, said the U.S.
N

GSK sues Moderna for US patent infringement over COVID, RSV vaccines

UPDATE 2-GSK sues Moderna for US patent infringement over COVID, RSV vaccines Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna Adds information about RSV vaccine claims in paragraphs 1 and 6 By Blake Brittain Oct 15 (Reuters) - British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S.
G
N
P

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.